Zymeworks Inc. 8-K

What Happened Zymeworks Inc. announced on June 29, 2026 (Merger Agreement dated June 28, 2026) that it has agreed to acquire Theravance Biopharma in a merger. At the closing each outstanding Theravance ordinary share will be cancelled and converted into $17.00 in cash plus one contingent value right (CVR). The boards of Zymeworks (Parent), its Merger Sub and Theravance approved the transaction following a unanimous recommendation from Theravance’s independent Strategic Review Committee. The parties expect the deal to close in the second half of 2026, subject to customary conditions including shareholder approval (two‑thirds vote), Hart‑Scott‑Rodino clearance, and absence of a continuing material adverse effect.

Key Details

• Per‑share consideration: $17.00 cash + 1 CVR per Theravance ordinary share.
• CVR economics: holders receive a pro rata share of (i) 80% of net proceeds from any license/divestiture of ampreloxetine within 10 years, (ii) a pro rata share of $50 million on first commercial sale of ampreloxetine in specified countries, and (iii) a pro rata share of 10% of net sales (royalties) subject to CVR Agreement terms. CVRs are non‑transferable contractual rights, not equity or tradable securities.
• Financing: Zymeworks has a debt commitment letter with OMERS Life Sciences to purchase up to $350 million of senior secured notes to help finance the transaction.
• Deal protections and timing: Termination and reverse‑termination fees of $32,515,000 apply in specified circumstances. The Merger Agreement contains customary covenants (e.g., non‑solicitation with fiduciary exceptions), treatment of equity awards (options/RSUs/PSUs converted to cash and CVRs), and termination of the company ESPP at closing. Outside date for closing is December 28, 2026 (with possible extensions for HSR timing).

Why It Matters This transaction changes Theravance from a public company to a wholly owned subsidiary of Zymeworks and delivers immediate cash consideration to Theravance shareholders plus potential future upside through CVRs tied to ampreloxetine commercialization or a license. Investors should note the deal depends on regulatory clearance and shareholder approval, and the CVRs provide contingent (not guaranteed) payments that depend on future licensing, sales or milestones. The announced OMERS financing commitment signals available debt capital for closing, but financing remains subject to customary conditions.